Breaking News Instant updates and real-time market news.

NXPI

NXP Semiconductors

$96.04

0.55 (0.58%)

, AB

AllianceBernstein

$28.69

0.58 (2.06%)

10:16
06/12/19
06/12
10:16
06/12/19
10:16

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Craig Hettenbach saying he sees relative value in the stock after the shares have underperformed peers by 73% during the last three years. 2. AllianceBernstein (AB) upgraded to Buy from Neutral at Goldman Sachs with analyst Alexander Blostein saying the company's "leading" organic fee growth is not priced into the shares at current levels. 3. Brinker (EAT) upgraded to Outperform from Market Perform at Telsey Advisory. 4. CymaBay (CBAY) upgraded to Strong Buy from Outperform at Raymond James with analyst Steven Seedhouse citing the upside potential he sees following the pullback in the stock. 5. CommScope (COMM) upgraded to Buy from Neutral at Rosenblatt with analyst Ryan Koontz saying "surging" fiber spending ahead of 5G buildouts, led by Verizon (VZ), improves the outlook of select companies in the communications equipment sector. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

NXPI

NXP Semiconductors

$96.04

0.55 (0.58%)

AB

AllianceBernstein

$28.69

0.58 (2.06%)

EAT

Brinker

$40.31

0.39 (0.98%)

CBAY

CymaBay

$6.23

0.185 (3.06%)

COMM

CommScope

$16.44

-0.07 (-0.42%)

  • 12

    Jun

  • 13

    Jun

  • 21

    Jun

  • 26

    Jun

  • 13

    Nov

NXPI NXP Semiconductors
$96.04

0.55 (0.58%)

06/12/19
MSCO
06/12/19
UPGRADE
Target $114
MSCO
Overweight
Morgan Stanley upgrades NXP Semiconductors to Overweight on relative value
As previously reported, Morgan Stanley analyst Craig Hettenbach upgraded NXP Semiconductors (NXPI) to Overweight from Equal Weight as he sees relative value in the stock after the shares have underperformed peers by 73% during the last three years. While peers such as Analog Devices (ADI), ON Semiconductor (ON), Maxim Integrated (MXIM) and Cypress Semiconductor (CY) have inventory levels at the high end or even above targets, NXP's inventory in distribution has stayed flat and is just below the mid-point of its target, said Hettenbach. As NXP's business recovers, he likes the company's ability to constrain spending to get it back in line with its target and drive operating margin, the analyst added. He also noted that the stock's multiple is at the biggest discount to peers in its history. Hettenbach raised his price target NXP shares to $114 from $99, but recommends an opportunistic approach when adding to positions given the ongoing risks of the current semiconductor cycle.
05/30/19
MSCO
05/30/19
UPGRADE
Target $15.5
MSCO
Equal Weight
Cypress Semiconductor upgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Craig Hettenbach upgraded Cypress Semiconductor to Equal Weight from Underweight and raised his price target for the shares to $15.50 from $11.50 following press reports indicating that the company is exploring strategic options. His new bull case value of $21 brings his valuation for the connectivity business in-line with the multiple NXP Semiconductors (NXPI) is paying for Marvell's (MRVL) connectivity business, but Hettenbach noted that if fundamentals deteriorate further and a deal does not take place, the stock could trade back down toward $11, which is his new bear case valuation.
06/12/19
MSCO
06/12/19
UPGRADE
MSCO
Overweight
NXP Semiconductors upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach upgraded NXP Semiconductors to Overweight from Equal Weight.
06/05/19
STFL
06/05/19
UPGRADE
Target $95
STFL
Hold
NXP Semiconductors upgraded to Hold from Sell at Stifel
Stifel analyst Tore Svanberg upgraded NXP Semiconductors to Hold from Sell and raised his price target for the shares to $95 from $85. The analyst sees reduced debt risk for the company amid the current "persistently" low-interest rate environment as well as reduced risk to estimates following cuts made since the Q3 of 2018 peak. Further, NXP has "meaningful" exposure to key secular growth cycles, especially 5G Infrastructure, Svanberg tells investors in a research note.
AB AllianceBernstein
$28.69

0.58 (2.06%)

06/12/19
GSCO
06/12/19
UPGRADE
Target $35
GSCO
Buy
AllianceBernstein upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Alexander Blostein upgraded AllianceBernstein to Buy from Neutral and raised his price target for the shares to $35 from $31.50. The company's "leading" organic fee growth is not priced into the shares at current levels, Blostein tells investors in a research note.
01/14/19
SBSH
01/14/19
NO CHANGE
SBSH
Citi gets more defensive on Brokers & Asset Managers, downgrades five
Citi analyst Citi analyst William Katz is taking a more defense stance on the traditional Brokers & Asset Managers to reflect what he sees as "weak" fundamentals and "still elevated" consensus estimates. The analyst reduced his target multiples across the group and downgraded Affiliated Managers (AMG) and Brightsphere Investment Group (BSIG) to Neutral from Buy as well as Artisan Partners (APAM), Waddell & Reed (WDR) and Franklin Resources (BEN) to Sell from Neutral. Katz calls Och-Ziff Capital (OZM) and LPL Financial (LPLA) his top ideas and also opened a "30 Day Positive Catalyst Watch" for Carlyle Group (CG) and Legg Mason (LM). The analyst recommends pair trades of Overweight AllianceBernstein (AB), underweight Artisan Partners (APAM), and overweight BlackRock (BLK), underweight T. Rowe Price (TROW).
EAT Brinker
$40.31

0.39 (0.98%)

06/11/19
EVER
06/11/19
INITIATION
Target $40
EVER
In Line
Brinker initiated with an In Line at Evercore ISI
Evercore ISI analyst David Palmer started Brinker with an In Line rating and $40 price target.
06/12/19
TLSY
06/12/19
UPGRADE
Target $47
TLSY
Outperform
Brinker upgraded to Outperform from Market Perform at Telsey Advisory
Telsey Advisory analyst Robert Derrington upgraded Brinker International to Outperform from Market Perform with a price target of $47.
06/03/19
06/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Black Knight (BKI) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying the company's "strong" pipeline of new bank client wins in both mortgage servicing and origination software should drive accelerating revenue growth over 2019 and into 2020 relative to recent quarters. 2. AMC Networks (AMCX) upgraded to In-Line from Underperform at Imperial Capital with analyst David Miller citing valuation. 3. BT Group (BT) upgraded to Outperform from Neutral at Credit Suisse with analyst Paul Sidney saying he has a "much increased" level of confidence in the company's ability to return to sustainable EBITDA growth in fiscal 2021. 4. Brinker (EAT) upgraded to Neutral from Sell at UBS with analyst Dennis Geiger saying that with the stock falling below that level, valuation now appears to reflect the challenges of his April initiation. 5. Teva (TEVA) upgraded to Outperform from Perform at Oppenheimer with analyst Esther Rajavelu saying the shares, trading at its 19-year low, offer a buying opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/03/19
06/03/19
UPGRADE
Target $39

Neutral
Brinker upgraded to Neutral from Sell at UBS
As previously reported, UBS analyst Dennis Geiger upgraded Brinker to Neutral with an unchanged price target of $39, saying that with the stock falling below that level, valuation now appears to reflect the challenges of his April initiation. The analyst notes that the company's sales are still expected to decelerate over the next few quarters, while cost headwinds should continue to weigh on earnings and margins in FY20.
CBAY CymaBay
$6.23

0.185 (3.06%)

06/12/19
CANT
06/12/19
NO CHANGE
Target $20
CANT
Overweight
CymaBay selloff yesterday brings buying opportunity, says Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle says the selloff yesterday in shares of CymaBay Therapeutics strengthens her conviction and presents a buying opportunity. The 52-week biopsy data in early 2020 "remain very much in play from a scientific perspective, but now with much greater upside potential from a stock perspective," Merle tells investors in a research note. While the analyst found the lack of fat benefit at week 12 surprising, she says her thesis on seladelpar in nonalcoholic steatohepatitis is that there are many biological reasons why the drug could show "strong" 52-biopsy data independent of fat changes. There is undue investor focus on MRI-PDFF, making NASH a "very large piece of optionality early next year," says the analyst. Merle reiterates an Overweight rating on CymaBay with a $20 price target. The stock closed yesterday down 45%, or $5.04, to $6.05.
06/11/19
RAJA
06/11/19
UPGRADE
Target $19
RAJA
Strong Buy
CymaBay upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded CymaBay to Strong Buy from Outperform citing the upside potential he sees following today's pullback in the stock. He keeps a $19 price target on the shares, calling today's reaction to the surrogate endpoint data "overblown."
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.
06/07/19
LEER
06/07/19
NO CHANGE
Target $22
LEER
Outperform
FDA news has 'nothing to do' with CymaBay's programs, says SVB Leerink
SVB Leerink analyst Pasha Sarraf says that CymaBay Therapeutics is down on an "overreaction" to the FDA's recommendation regarding endpoint for compensated cirrhosis. In a research note to investors , Sarraf says he recommends purchasing at these levels, saying he continues to believe the the stock is likely to pop on the interim results from the MRI-PDFF results, which have not yet been announced and feels the FDA's announcement regarding compensated cirrhosis has "absolutely nothing to do" with CymaBay's programs. Sarraf has an Outperform rating and $22 price target on CymaBay shares.
COMM CommScope
$16.44

-0.07 (-0.42%)

06/05/19
MSCO
06/05/19
UPGRADE
Target $22
MSCO
Overweight
CommScope upgraded to Overweight following selloff at Morgan Stanley
As previously reported, Morgan Stanley analyst Meta Marshall upgraded CommScope Holding to Overweight from Equal Weight, citing her view that the valuation has become attractive following a greater than 25% selloff in the stock since the company reported Q1 results and her belief that its results should improve in the second half. Marshall, who thinks the market is missing the eventual earnings power of the combination of CommScope with Arris, particularly as debt gets paid down, trimmed her price target on the stock to $22 from $24.
06/12/19
RSBL
06/12/19
UPGRADE
Target $22
RSBL
Buy
CommScope upgraded to Buy from Neutral at Rosenblatt
Rosenblatt analyst Ryan Koontz upgraded CommScope to Buy from Neutral while lowering his price target for the shares to $22 from $24. "Surging" fiber spending ahead of 5G buildouts, led by Verizon (VZ), improves the outlook of select companies in the communications equipment sector, Koontz tells investors in a research note. Further, he expects CommScope to see improved cable sales in the second half of 2019 ahead of a border 5G deployment in 2020.
04/22/19
JPMS
04/22/19
NO CHANGE
JPMS
JPMorgan a buyer of Ciena and Lumentum into Q1 results, downgrades Sensata
JPMorgan analyst Samik Chatterjee names Ciena (CIEN) and Lumentum (LITE) his top Networking Equipment picks into the Q1 reporting season. The analyst is a buyer of both stocks into the prints. Following the rallies year-to-date, investors might need to be more selective relative to opportunities for further share price upside heading into earnings, Chatterjee tells investors in a pre-earnings research note. He believes the overall capital expenditure environment remains positive and that momentum into 5G investment spend appears to be building, particularly in North America. This is likely provide greater visibility to companies relative to their already stated full-year targets, says Chatterjee. However, with investor optimism around 5G infrastructure investment as well as the positive impact on growth from a potential U.S.-China trade deal, the analyst expects share price performances to be largely muted on the back of Q1 earnings. Nonetheless, he sees upside opportunity in both Ciena and Lumentum. Chatterjee also reinstated coverage of CommScope (COMM) and upgraded the shares to Overweight from Neutral, upgraded Viavi Solutions (VIAV) to Neutral from Underweight, and downgraded Sensata (ST) to Neutral from Overweight. A further multiple re-rating of Sensata shares appears unlikely in an environment of moderating auto production this year, contends the analyst.
06/05/19
MSCO
06/05/19
UPGRADE
MSCO
Overweight
CommScope upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Meta Marshall upgraded CommScope Holding to Overweight from Equal Weight.

TODAY'S FREE FLY STORIES

HXL

Hexcel

$78.42

(0.00%)

05:12
06/24/19
06/24
05:12
06/24/19
05:12
Hot Stocks
Hexcel announces voluntary delisting from Euronext Paris »

Hexcel announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

EVA

Enviva

$29.50

-0.24 (-0.81%)

05:11
06/24/19
06/24
05:11
06/24/19
05:11
Upgrade
Enviva rating change  »

Enviva upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$165.16

-1.8 (-1.08%)

05:10
06/24/19
06/24
05:10
06/24/19
05:10
Hot Stocks
Motorola Solutions awarded tender for supplying POC service to Israel Railways »

Motorola Solutions has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

CNTY

Century Casinos

$9.83

-0.3 (-2.96%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Century Casinos management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

CNCE

Concert Pharmaceuticals

$10.90

-0.165 (-1.49%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Concert Pharmaceuticals management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

ATH

Athene Holding

$42.58

-0.8 (-1.84%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Athene Holding management to meet with Sandler O'Neill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

SSTI

ShotSpotter

$44.50

0.19 (0.43%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
ShotSpotter management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

ATH

Athene Holding

$42.58

-0.8 (-1.84%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Athene Holding management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

HUBG

Hub Group

$40.70

-1.25 (-2.98%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Hub Group management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 13

    Nov

SPOT

Spotify

$148.17

-1.57 (-1.05%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Spotify management to meet with SunTrust »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

INGN

Inogen

$71.29

-1.37 (-1.89%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
William Blair medical tech analyst to hold a luncheon »

Medical Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 26

    Aug

STXB

Spirit of Texas Bancshares

$22.49

0.07 (0.31%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Spirit of Texas Bancshares management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Dallas Fed Mfg Survey General Activity Index to be reported at 10:30 »

June Dallas Fed Mfg…

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

INWK

InnerWorkings

$4.17

(0.00%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
InnerWorkings management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

OKTA

Okta

$130.77

-2.63 (-1.97%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Okta management to meet with KeyBanc »

Dinner Meeting with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

STFC

State Auto Financial

$34.64

-0.18 (-0.52%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
State Auto Financial management to meet with Sandler O'Neill »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

ABT

Abbott

$85.04

0.07 (0.08%)

, EVTCY

Evotec

$0.00

(0.00%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
American Society for Microbiology to hold a conference »

ASM Microbe 2019 will be…

ABT

Abbott

$85.04

0.07 (0.08%)

EVTCY

Evotec

$0.00

(0.00%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

TTPH

Tetraphase

$0.63

-0.02 (-3.10%)

PRTK

Paratek Pharmaceuticals

$3.77

(0.00%)

TMO

Thermo Fisher

$294.45

1.06 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 02

    Dec

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
JPMorgan U.S. energy team to hold an analyst/industry conference call »

U.S. Energy Analyst…

SCS

Steelcase

$15.46

-0.32 (-2.03%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Steelcase management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 26

    Jun

  • 10

    Jul

04:55
06/24/19
06/24
04:55
06/24/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

CLF

Cleveland-Cliffs

$10.04

-0.21 (-2.05%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Cleveland-Cliffs management to meet with B. Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

ENS

EnerSys

$65.77

0.4003 (0.61%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
EnerSys management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

GES

Guess

$14.88

0.27 (1.85%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Guess management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

JWN

Nordstrom

$33.43

0.22 (0.66%)

04:55
06/24/19
06/24
04:55
06/24/19
04:55
Conference/Events
Nordstrom management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.